Sam-A Pharm Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sam-A Pharm.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 31.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Take Care Before Jumping Onto Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Even Though It's 26% Cheaper
Dec 06
Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?
Nov 13Earnings Working Against Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Share Price Following 34% Dive
Aug 25Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Price Is Right But Growth Is Lacking After Shares Rocket 32%
Jul 11Should You Be Adding Sam-A Pharm (KOSDAQ:009300) To Your Watchlist Today?
Jun 21Sam-A Pharm. Co., Ltd's (KOSDAQ:009300) Shares Bounce 26% But Its Business Still Trails The Market
May 25Key Things To Consider Before Buying Sam-A Pharm. Co., Ltd (KOSDAQ:009300) For Its Dividend
Apr 08Is Sam-A Pharm (KOSDAQ:009300) A Risky Investment?
Mar 04How Much Did Sam-A Pharm's(KOSDAQ:009300) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 28
Four Days Left To Buy Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Before The Ex-Dividend Date
Dec 24Sam-A Pharm. Co., Ltd (KOSDAQ:009300) Is Yielding 1.6% - But Is It A Buy?
Dec 07In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sam-A Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 101,393 | 22,768 | 25,827 | 32,527 | N/A |
| 6/30/2024 | 102,550 | 24,744 | 24,655 | 30,253 | N/A |
| 3/31/2024 | 102,511 | 23,936 | 25,294 | 30,074 | N/A |
| 12/31/2023 | 97,211 | 21,374 | 17,204 | 20,760 | N/A |
| 9/30/2023 | 95,931 | 20,338 | 16,342 | 18,144 | N/A |
| 6/30/2023 | 95,324 | 20,387 | 15,492 | 15,844 | N/A |
| 3/31/2023 | 87,159 | 15,531 | 17,967 | 17,536 | N/A |
| 12/31/2022 | 81,700 | 11,912 | 20,465 | 19,604 | N/A |
| 9/30/2022 | 75,479 | 11,029 | 17,431 | 15,629 | N/A |
| 6/30/2022 | 66,172 | 7,520 | 17,817 | 16,940 | N/A |
| 3/31/2022 | 63,638 | 7,000 | 13,683 | 12,874 | N/A |
| 12/31/2021 | 54,666 | 3,392 | 13,717 | 12,943 | N/A |
| 9/30/2021 | 50,907 | 178 | 14,005 | 13,670 | N/A |
| 6/30/2021 | 50,870 | -1,115 | 9,148 | 9,078 | N/A |
| 3/31/2021 | 48,548 | -1,650 | 9,937 | 10,177 | N/A |
| 12/31/2020 | 53,653 | 124 | 9,056 | 9,408 | N/A |
| 9/30/2020 | 59,775 | 3,392 | 10,004 | 9,389 | N/A |
| 6/30/2020 | 64,025 | 5,986 | 14,968 | 14,092 | N/A |
| 3/31/2020 | 70,346 | 9,128 | 14,889 | 13,867 | N/A |
| 12/31/2019 | 71,560 | 10,197 | 14,285 | 13,221 | N/A |
| 9/30/2019 | 70,715 | 9,807 | 12,485 | 14,334 | N/A |
| 12/31/2018 | 66,947 | 8,801 | 10,357 | 12,755 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if A009300's forecast earnings growth is above the savings rate (2.7%).
Earnings vs Market: Insufficient data to determine if A009300's earnings are forecast to grow faster than the KR market
High Growth Earnings: Insufficient data to determine if A009300's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if A009300's revenue is forecast to grow faster than the KR market.
High Growth Revenue: Insufficient data to determine if A009300's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if A009300's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 05:00 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sam-A Pharm. Co., Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|